Remus Pharmaceuticals Ltd (REMUS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Remus Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording
Audio / Video · 04 Nov 2026, 8:11 pm
Remus Pharmaceuticals Releases Audio Recording for H1-FY27 Earnings Conference Call Remus Pharmaceuticals Limited conducted an Earnings Conference Call on 4th Nov'26 with analysts and institutional investors to discuss its Unaudited Standalone and Consolidated Financial Results for the half-year ended 30th Sep'26 (H1-FY27). In compliance with SEBI LODR Regulations, the company confirmed that the complete audio recording of the call is accessible on its investor relations website, with no unpublished price-sensitive information shared during the interaction.
Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation
Investor Presentation · 04 Nov 2026, 5:32 pm
Remus Pharmaceuticals H1-FY27 Financial and Operational Performance Overview Remus Pharmaceuticals delivered a strong H1-FY27 consolidated performance, with operational revenue rising 53.4% YoY to INR 6,141 Mn, EBITDA increasing 11.2% YoY to INR 299 Mn, and PAT growing 14.4% YoY to INR 247 Mn. Standalone revenue and PAT grew 32.4% and 56.7% YoY to INR 621 Mn and INR 188 Mn, respectively. The company expanded its pipeline to 955+ approved products across 2,443+ global registrations and dossiers, won a 24-product tender in Bolivia, obtained Peruvian Digemid plant approval, and secured approval for Semaglutide formulations.
Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026
Press Release · 03 Nov 2026, 9:46 pm
Remus Pharmaceuticals Reports Strong H1 FY27 Results with 53.45% Consolidated Revenue Growth Remus Pharmaceuticals reported H1 FY27 consolidated revenue of ₹614.12 Cr, up 53.45% YoY and 35.44% vs H2 FY26. Consolidated EBITDA rose 11.22% YoY to ₹29.93 Cr, while PAT grew 14.22% YoY to ₹24.66 Cr, impacted by setup and operating costs across Bolivia, Guatemala, and Espee GCTS subsidiaries. Standalone revenue jumped 32.51% YoY to ₹62.08 Cr, with PAT expanding 56.37% YoY to ₹18.81 Cr. Key operational milestones include securing Semaglutide approvals, winning a 24-product tender in Bolivia, and obtaining DIGEMID plant approval in Peru.
Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026.
Dividend · 03 Nov 2026, 9:32 pm
Remus Pharmaceuticals Sets Record Date for First Interim Dividend for FY27 Remus Pharmaceuticals Limited has fixed Saturday, 7th Nov'26, as the record date to determine shareholder eligibility for the payment of its first interim dividend for FY26-27, pursuant to board approval on 3rd Nov'26. The company confirmed that dividend disbursements to eligible equity shareholders will be completed within the statutory timelines mandated by the Companies Act, 2013.
Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share.
Outcome · 03 Nov 2026, 9:29 pm
Remus Pharmaceuticals H1 FY27 Results and Interim Dividend Declaration Remus Pharmaceuticals declared an interim dividend of Rs 1.00 per share (record date: 7th Nov'26) alongside its H1 FY27 results. Consolidated revenue surged 53.45% YoY to Rs 614.12 Cr, while EBITDA grew 11.22% YoY to Rs 29.93 Cr and PAT increased 14.22% YoY to Rs 24.66 Cr. Consolidated margins absorbed setup and operating costs from newly acquired subsidiaries across Bolivia, Guatemala, and Espee GCTS. Operational milestones included securing government tenders in Bolivia and Venezuela, along with approvals for Semaglutide tablets/injections and Rotigotine patches.
Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026
Outcome · 03 Nov 2026, 9:28 pm
Remus Pharmaceuticals H1 FY27 Consolidated Revenue Up 53% YoY; Declares Interim Dividend Remus Pharmaceuticals posted strong H1 FY27 consolidated financial results, with revenue from operations surging 53.45% YoY to ₹614.12 crore compared to ₹400.20 crore in H1 FY26. Consolidated EBITDA rose 11.22% YoY to ₹29.93 crore, while PAT grew 14.22% YoY to ₹24.66 crore, despite initial setup and operating cost drags from new subsidiaries. The board approved a first interim dividend of ₹1.00 per equity share (face value ₹10) for FY 2026-27, with the record date set for 7th Nov'26.
Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Intimation · 29 Oct 2026, 12:39 am
Remus Pharmaceuticals Schedules H1 FY27 Earnings Conference Call Remus Pharmaceuticals Limited will host an earnings conference call on 4th Nov'26 at 12:00 PM IST to discuss its unaudited standalone and consolidated financial results for the half year ended 30th Sep'26 (H1 FY27). The management will be represented by Managing Director Arpit Shah and Chief Financial Officer Bhavik Shah. Universal dial-in access numbers include +91 22 6280 1341 and +91 22 7115 8242, with international toll-free options available. The call recording and transcript will subsequently be made available on the company's website.
Remus Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend/Other business.
Intimation · 03 Nov 2026, 5:30 am
Remus Pharmaceuticals Schedules Board Meeting for H1FY27 Financials and Dividend Remus Pharmaceuticals Limited has informed the Exchange that its Board of Directors will meet on 3rd Nov'26. The board will consider and approve the unaudited financial results for the half-year ended Sep'26, alongside evaluating a potential dividend declaration and other general business matters.
To consider and approve the financial results for the period ended September 30, 2026, interim dividend and other business matters
Intimation · 03 Nov 2026, 5:30 am
Remus Pharmaceuticals Board to Consider H1 FY27 Results and Interim Dividend Remus Pharmaceuticals Limited has scheduled a Board of Directors meeting for 3rd Nov'26. The board will consider and approve the unaudited standalone and consolidated financial results for the half-year ended 30th Sep'26, accompanied by the limited review report. Additionally, the board will evaluate a proposal to declare a 1st interim dividend on equity shares for FY27. In compliance with insider trading regulations, the trading window for dealing in company securities remains closed from 1st Oct'26 until 48 hours post-result declaration.
Remus Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizer report and voting results for Postal Ballot
Annual General Meeting · 08 Oct 2026, 12:45 am
Remus Shareholders Approve Migration to NSE and BSE Main Boards Remus Pharmaceuticals Limited announced that its shareholders approved a special resolution via postal ballot to migrate listing and trading of equity shares from NSE Emerge to the main boards of NSE and BSE. The remote e-voting concluded on 6th Oct'26 with 100% of the 238,600 valid public votes cast in favor and zero against, fulfilling Regulation 277 SEBI ICDR requirements. Promoter and promoter group entities did not participate in the vote, and the resolution passed with the requisite majority.
Remus Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 11th Annual General Meeting
Annual General Meeting · 30 Sept 2026, 10:30 pm
Remus Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2026
Annual General Meeting · 29 Sept 2026, 11:57 pm
Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 22-Sep-2026.
Dividend · 08 Sept 2026, 2:30 am
Remus Pharmaceuticals Sets Record Date for FY26 Final Dividend Remus Pharmaceuticals has fixed 22nd Sep'26 as the record date to determine shareholder eligibility for a final dividend of Rs. 0.50 per fully paid-up equity share (face value Rs. 10 each) for FY26. The dividend is subject to shareholder approval at the upcoming Annual General Meeting scheduled for 29th Sep'26. Upon approval, the dividend will be disbursed within 30 days, subject to applicable tax deducted at source.
Remus Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026
Annual General Meeting · 08 Sept 2026, 2:28 am
Remus Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
Annual General Meeting · 05 Sept 2026, 7:40 pm
Remus Pharmaceuticals Seeks Shareholder Approval for Main Board Migration Remus Pharmaceuticals Limited issued a Postal Ballot Notice seeking shareholder approval via special resolution to migrate its equity shares (face value ₹10.00) from the NSE Emerge platform to the Main Boards of NSE and BSE. The cut-off date for voting eligibility is 28th Aug'26. Remote e-voting runs from 7th Sep'26 to 6th Oct'26, with results announced on or before 8th Oct'26. The migration aims to enhance liquidity, visibility, and broader investor participation, subject to statutory approvals and non-promoter voting thresholds per SEBI ICDR regulations.
Remus Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of a Subsidiary in Dominican Republic
Outcome · 03 Sept 2026, 12:01 am
Remus Pharmaceuticals Approves Main Board Migration and New Dominican Republic Subsidiary On 2nd Sep'26, Remus Pharmaceuticals approved the migration of its shares from the NSE Emerge platform to the NSE and BSE Main Boards, pending shareholder and regulatory approvals. The Board also authorized forming a pharmaceutical supply and distribution subsidiary in the Dominican Republic, with Remus acquiring a 51% or greater equity stake via cash consideration. Additionally, experienced FMCG entrepreneur Ashutosh Naginbhai Valani was appointed as a Non-Executive Independent Director for a five-year term, effective immediately.
Remus Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Ashutosh Naginbhai Valani as Non- Executive Independent Director of the company w.e.f. September 02, 2026.
Outcome · 02 Sept 2026, 11:59 pm
Remus Pharma Approves Main Board Migration, Dominican Subsidiary, and Director Appointment On 2nd Sep'26, Remus Pharmaceuticals approved its migration from the NSE Emerge platform to the NSE and BSE Main Boards, subject to shareholder and regulatory approvals. The Board also authorized incorporating a pharmaceutical distribution subsidiary in the Dominican Republic to support global expansion, with Remus acquiring a 51%+ stake via cash consideration. Furthermore, entrepreneur Ashutosh Valani was appointed as a Non-Executive Independent Director for a five-year term to strengthen corporate governance and strategic oversight.
Remus Pharmaceuticals Limited has informed regarding Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 07 Jul 2026, 11:19 pm
Remus Pharma Exempt from Filing Corporate Governance Reports On 07 Jul'26, Remus Pharmaceuticals informed the NSE that it is exempt from filing corporate governance reports under Regulation 27(2) of SEBI (LODR) Regulations, 2015. The exemption applies as the company's equity shares are listed on the NSE's SME Emerge Platform, fulfilling the non-applicability criteria specified in Regulation 15(2)(b). Consequently, Remus is not required to submit quarterly, half-yearly, or yearly governance reports.